LOADING

Type to search

AstraZeneca COVID-19 antibody therapies Entertainment Science & Technology

AstraZeneca accelerates testing of COVID-19 antibody treatments

Share
AstraZeneca accelerates testing of COVID-19 antibody treatments
[ad_1]

AstraZeneca mentioned on Tuesday it expects to maneuver two COVID-19 antibody therapies it has licensed from US researchers into scientific research within the subsequent two months because the drugmaker ramps up efforts to assist fight the well being disaster.

The British firm mentioned it has agreed phrases with the United States’ Defense Advanced Research Projects Agency (DARPA) and Biomedical Advanced Research and Development Authority (BARDA) to again its undertaking to develop a monoclonal antibody therapy in opposition to the coronavirus.

The firm didn’t disclose the monetary phrases of the agreements.

The United States has already secured 300 million doses of AstraZeneca’s experimental COVID-19 vaccine, AZD1222, by pledging greater than $1 billion by BARDA and has poured billions extra into different tasks to make sure provide.

While some promising vaccine candidates have emerged within the international race to discover a answer for the sickness brought on by the brand new coronavirus, many within the medical neighborhood imagine antibody-based therapies maintain nice potential.

AstraZeneca additionally mentioned on Tuesday it has licensed six candidates from Vanderbilt University in Nashville, Tennessee, after evaluating greater than 1,500 potential monoclonal antibodies. Two of these six potential proteins might be examined as a mixture method for COVID-19.

Antibodies are generated within the physique to struggle off an infection. Monoclonal antibodies mimic pure antibodies and will be remoted and manufactured in massive portions to deal with illnesses in sufferers.

There are at the moment no permitted remedies or vaccines for COVID-19.

[ad_2]

Leave a Reply